Fidelity Investments’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,997
| Closed | -$11.7K | – | 5632 |
|
|
2022
Q4 | $11.7K | Buy |
+1,997
| New | +$10.5K | ﹤0.01% | 3955 |
|
|
2021
Q4 | – | Sell |
-775
| Closed | -$3K | – | 5140 |
|
|
2021
Q3 | $3K | Buy |
775
+355
| +85% | +$1.24K | ﹤0.01% | 3956 |
|
|
2021
Q2 | $2K | Buy |
420
+20
| +5% | +$85 | ﹤0.01% | 3976 |
|
|
2021
Q1 | $2K | Buy |
+400
| New | +$3.23K | ﹤0.01% | 3770 |
|
|
2018
Q4 | – | Sell |
-61
| Closed | -$1K | – | 4316 |
|
|
2018
Q3 | $1K | Buy |
+61
| New | +$960 | ﹤0.01% | 3477 |
|
|
2017
Q1 | – | Sell |
-100,000
| Closed | -$1.03M | – | 2722 |
|
|
2016
Q4 | $1.03M | Buy |
100,000
+15,056
| +18% | +$138K | ﹤0.01% | 2468 |
|
|
2016
Q3 | $859K | Buy |
84,944
+29,769
| +54% | +$325K | ﹤0.01% | 2480 |
|
|
2016
Q2 | $620K | Buy |
+55,175
| New | +$703K | ﹤0.01% | 2521 |
|
|
2016
Q1 | – | Sell |
-180,925
| Closed | -$3.43M | – | 2761 |
|
|
2015
Q4 | $3.43M | Buy |
180,925
+5,000
| +3% | +$109K | ﹤0.01% | 2302 |
|
|
2015
Q3 | $3.3M | Buy |
+175,925
| New | +$2.99M | ﹤0.01% | 2287 |
|
|
2014
Q4 | – | Sell |
-33,953
| Closed | -$428K | – | 2862 |
|
|
2014
Q3 | $428K | Buy |
+33,953
| New | +$329K | ﹤0.01% | 2649 |
|
Fidelity Investments's CNCE Position: Q1 2023 in Review
Fidelity Investments sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,997 shares — an estimated $11.7K sold.
Fidelity Investments first reported a position in CNCE in Q3 2014 and held it in 11 quarters. The position peaked at $3.43M in Q4 2015. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Fidelity Investments reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Fidelity Investments sold 1,997 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.7K.
- Fidelity Investments first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
- Fidelity Investments's Concert Pharmaceuticals, Inc. position peaked at $3.43M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Fidelity Investments's 13F filing for Q1 2023, filed 11 May 2023.